氘可来昔替尼(Deucravacitinib)治疗斑块状银屑病的有效性？

Deuterated colexitinib not only shows significant effectiveness in the treatment of plaque psoriasis, but also has a good performance in terms of safety.

In two III clinical trials, POETYK PSO1 and POETYK PSO-2, a large number of patients with plaque psoriasis were enrolled to evaluate the efficacy and safety of deuterated colexitinib. The trial results showed that at the 16th week of treatment, the PASI 75 response rate of the deuterated colexitinib group was significantly higher than that of the apremilast group and placebo group, and the safety profile was also better.

Deuterated colexitinib

It is a new oral inhibitor of tyrosine kinase 2 (TYK2) that works through an allosteric mechanism, binds to the catalytically inactive pseudokinase regulatory domain of TYK2, and stabilizes the inhibitory interaction between the regulatory and catalytic domains. It is suitable for the treatment of adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy.

Deucravacitinib for the treatment of plaque psoriasis

The efficacy and safety of deuterated colexitinib 6 mg once daily were evaluated in two multicenter, randomized, double-blind, placebo- and active-controlled clinical trials, PSO-1 and PSO-2, in subjects 18 years and older with moderate-to-severe plaque psoriasis with ≥10% body surface area (BSA) involvement who were eligible for systemic therapy or phototherapy.

In PSO-1 and PSO-2, a total of 1,684 patients were randomly assigned to receive colexitinib, placebo, or apremilast. At weeks 16 and 24, PSO-1 and PSO-2 reached PASI 75, PASI 90, and sPGA 0/1 and improved by at least 2 grades compared to baseline.

At week 16, the PASI 75 response rate was 58% in the colexitinib group, 13% in the placebo group, and 35% in the apremilast group, achieving sPGA 0 and ss-PGA 0/1 and improving at least 2 grades from baseline.

At week 24, the response rate to PASI 75 was 69% in the colexitinib group, non-responders in the placebo group, and 38% in the apremilast group.

In patients with moderate to severe plaque psoriasis, treatment with deuterated colexitinib resulted in early responses with similar trends across multiple efficacy measures and improvement in quality of life. Deucravacitinib has the potential to be a promising new oral drug for the treatment of this disease.

Deuterated colexitinib price

Deuterated colexitinib has been marketed in the United States, the European Union and other countries, but it is not currently available in China. It is understood that the reference price of deuterated colexitinib produced by Bristol-Myers Squibb, 6mgx30 specifications, is about $83,415 per box, which is relatively expensive and cannot be reimbursed by medical insurance.

Deuterated colexitinib from Ziska Pharmaceutical Factory in Bangladesh is relatively cheap. The current reference price of the drug in 6 mg People who need to purchase medicines can choose appropriate drug versions for treatment according to their own conditions.

Recommended related articles: